India & China must-win markets on rising middle-class households: Reckitt Chief

Reckitt Benckiser sees India and China as vital growth markets. The company's CEO highlighted the expanding middle class in these nations. Emerging markets are driving Reckitt's revenue expansion. India and China showed strong growth in the last quarter. This performance helped offset weaker results in developed markets. Reckitt aims to increase its reach in India through improved distribution.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/90FKEjL
via IFTTT

Read More

Iran war could disrupt India’s pharma exports by up to $500 million

The Iran war is impacting India's drug exports. Higher freight costs and shipping refusals to Gulf hubs are causing concern. Industry estimates suggest a potential loss of $300-$500 million. While manufacturing remains unaffected, logistics are complicated. Companies are maintaining inventories to ensure supply continuity. The situation could lead to temporary supply challenges.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/j9pxiSV
via IFTTT

Read More

India pharma exports risk disruption if Middle East conflict widens

Indian drug exports face significant challenges. A wider Middle East conflict could disrupt vital shipping routes. This may lead to longer transit times for temperature-sensitive medicines. Increased freight costs and potential delays in key markets like the UAE and Saudi Arabia are also concerns. Air cargo routes are also at risk.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/LhIpoxs
via IFTTT

Read More

Urban India faces metabolic health crisis as 73 million are overweight or obese

In India's vibrant urban landscape, obesity and diabetes are becoming formidable adversaries. A new analysis highlights that while countless individuals are caught in the grip of these health challenges, there's a startling lack of awareness about innovative GLP-1 weight loss medications. Interestingly, informed individuals express considerable eagerness to explore these options.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/35PxcKE
via IFTTT

Read More

Ahead of its time, a GLP-1 drug almost made it out of India

Fifteen years back, Zydus Lifesciences introduced ZYOG1, an oral GLP-1 agonist that sparked excitement for its implications in diabetes management and weight loss. Unfortunately, due to prohibitive clinical trial costs and a skeptical outlook on the obesity market, Zydus chose to shelve further development.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/bFBIjhY
via IFTTT

Read More

Child hears again 18 months after brain stem implant at AIIMS

A young boy in India has received a groundbreaking auditory brain stem implant. This marks a first for AIIMS. The surgery was performed after conventional implants were not suitable. The child is now responding to sounds and speaking more clearly. Doctors highlight the importance of early detection for hearing loss.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/DiS2nva
via IFTTT

Read More

NATCO Pharma launches generic blood cancer treatment medicine in US

NATCO Pharma has launched generic Pomalidomide capsules in the US. This drug treats blood and bone marrow cancer. It is a generic version of Celgene's Pomalyst. The launch is in partnership with Breckenridge Pharmaceutical. This move aims to make specialty medicines accessible. It offers an affordable solution for patients.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/845bQ6z
via IFTTT

Read More